{"disease":{"id":"blau-syndrome","name":"blau syndrome"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00001244","title":"Immune Regulation in Patients With Common Variable Immunodeficiency and Related Inborn Errors of Immunity (IEI)","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT06206811","title":"Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"Odyssey Therapeutics","has_results":false},{"nct_id":"NCT06660329","title":"Efficacy and Safety of Tofacitinib in Refractory Blau Syndrome","phase":"PHASE4","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT06688838","title":"Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":24,"lead_sponsor_name":"Tongji Hospital","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}